Engaging Insights from Kairos Pharma at Maxim Healthcare Summit
LOS ANGELES – Kairos Pharma Ltd. (NYSE American: KAPA), a prominent clinical-stage biopharmaceutical company, is excited to announce an engaging opportunity at the upcoming Maxim Healthcare Virtual Summit. This virtual event is set to provide crucial insights into the latest developments in the healthcare sector, and Kairos is positioned to be at the forefront of these discussions. John S. Yu, M.D., the company's Chief Executive Officer, will be featured in a fireside chat, covering essential topics related to oncology and its therapeutic advancements.
Fireside Chat Details
John S. Yu is scheduled to converse with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group. This chat will take place on October 17, 2024, at 1:00 PM ET, making it a highlight of the summit. Attendees will gain invaluable knowledge about the evolving landscape of biopharmaceuticals and how Kairos Pharma plays a pivotal role in innovation.
About the 2024 Maxim Healthcare Virtual Summit
The Maxim Healthcare Virtual Summit brings together leading experts, innovators, and stakeholders in the healthcare industry to share insights and drive forward-thinking discussions about the future of medical treatments and technologies. This platform is particularly crucial for understanding how companies like Kairos Pharma are addressing significant challenges in cancer treatment.
Kairos Pharma’s Mission in Oncology
Kairos Pharma Ltd. is committed to combating cancer through innovative treatment approaches. The company focuses on using structural biology to tackle common issues such as drug resistance and immune suppression encountered in cancer therapies. Their flagship product, ENV105, specifically targets CD105, a molecule associated with cancer treatment resistance. By inhibiting CD105, ENV105 aims to enhance the effectiveness of existing standard therapies, potentially providing new hope for patients battling various cancer types.
Clinical Advancements and Future Directions
Currently, ENV105 is undergoing crucial Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer. These trials are significant as they address unmet medical needs and aim to shift the paradigms of cancer treatment. The progress of these studies will play a substantial role in shaping the future of oncology therapeutics, and the insights shared at the Maxim Summit will highlight Kairos Pharma’s contributions and strategies.
Engagement with Investors and the Public
Kairos Pharma is dedicated to maintaining transparency and open communication with stakeholders. The participation in the Maxim Healthcare Virtual Summit not only serves to inform the healthcare community about their advancements but also fosters engagement with investors who are keenly interested in the company’s potential and future directions.
Looking Ahead: Opportunities for Growth
As the biopharmaceutical landscape continues to evolve, Kairos Pharma’s strategic initiatives aim to address the pressing health challenges faced globally. By focusing on innovative solutions and fostering collaborations within the healthcare sector, the company strives to enhance its impact on patient outcomes and further solidify its position as a leader in oncology therapeutics.
Frequently Asked Questions
What is the main focus of Kairos Pharma?
Kairos Pharma focuses on developing innovative cancer therapies, particularly targeting drug resistance.
Who will be speaking at the Maxim Healthcare Virtual Summit?
John S. Yu, M.D., CEO will be speaking with Jason McCarthy, Ph.D., during the summit.
When is the fireside chat scheduled?
The fireside chat is scheduled for October 17, 2024, at 1:00 PM ET.
What is ENV105?
ENV105 is Kairos Pharma's lead candidate targeting CD105, aiming to overcome drug resistance in cancer treatment.
How can I learn more about Kairos Pharma?
For further information, you can visit their official website at kairospharma.com.